期刊
JOURNAL OF INVESTIGATIVE DERMATOLOGY
卷 141, 期 1, 页码 84-+出版社
ELSEVIER SCIENCE INC
DOI: 10.1016/j.jid.2020.05.098
关键词
-
类别
资金
- Austrian Science Fund [P-27001-B13, P-29919-B26]
- Cancer Research UK [A21025]
- Bright Red Funding
- German Research Foundation (DFG) [RA1944/6-1]
Langerhans cells in the skin, critical for immune response and skin homeostasis, can be generated from monocytes with specific cytokines and ligands. These monocyte-derived LCs show potential for vaccine testing and can be an effective tool for future research.
Langerhans cells (LCs) in the skin are a first line of defense against pathogens but also play an essential role in skin homeostasis. Their exclusive expression of the C-type lectin receptor Langerin makes them prominent candidates for immunotherapy. For vaccine testing, an easily accessible cell platform would be desirable as an alternative to the time-consuming purification of LCs from human skin. Here, we present such a model and demonstrate that monocytes in the presence of GM-CSF, TGF-beta 1, and the Notch ligand DLL4 differentiate within 3 days into CD1a(+)Langerin(+) cells containing Birbeck granules. RNA sequencing of these monocyte-derived LCs (moLCs) confirmed gene expression of LC-related molecules, pattern recognition receptors, and enhanced expression of genes involved in the antigen-presenting machinery. On the protein level, moLCs showed low expression of costimulatory molecules but prominent expression of C-type lectin receptors. MoLCs can be matured, secrete IL-12p70 and TNF-alpha, and stimulate proliferation and cytokine production in allogeneic CD4(+) and CD8(+) T cells. In regard to vaccine testing, a recently characterized glycomimetic Langerin ligand conjugated to liposomes demonstrated specific and fast internalization into moLCs. Hence, these short-term in vitro-generated moLCs represent an interesting tool to screen LC-based vaccines in the future.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据